Markets:

Overview

News

Currencies

International

Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.130 -0.020 (-0.48%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged ↗

June 15, 2023

The company is testing a treatment for a form of ovarian cancer.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 15, 2023

Via Benzinga

Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday ↗

June 15, 2023

Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%...

Via Benzinga

Verastem: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead' ↗

March 30, 2023

Via Benzinga

Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN

June 05, 2023

Via AB Newswire

AI Boom Wanes In June: Nvidia Falls Under $1T As Benzinga Reviews May's Champions ↗

June 01, 2023

Via Benzinga

Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

June 01, 2023

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

Via FinancialNewsMedia

Verastem Oncology Announces Reverse Stock Split

May 31, 2023

From Verastem Oncology

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 29, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 26, 2023

Via Benzinga

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

May 25, 2023

From Verastem Oncology

Via Business Wire

Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 26, 2023

Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.

Via Benzinga

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

May 16, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 09, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in Upcoming Investor Conferences

May 01, 2023

From Verastem Oncology

Via Business Wire

New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

April 26, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

April 18, 2023

From Verastem Oncology

Via Business Wire

7 Very Undervalued Penny Stocks to Buy in April 2023 ↗

April 06, 2023

Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.

Via InvestorPlace

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 06, 2023

From Verastem Oncology

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗

March 30, 2023

Via Benzinga

New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

March 15, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

March 14, 2023

From Verastem Oncology

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 06, 2023

Via Benzinga

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

February 02, 2023

From Verastem Oncology

Via Business Wire

Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 27, 2023

Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test.

Via Benzinga

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

January 24, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

January 24, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 18, 2023

From Verastem Oncology

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.